Earnings Call Summary | Delcath Systems(DCTH.US) Q3 2024 Earnings Conference
Earnings Call Summary | Delcath Systems(DCTH.US) Q3 2024 Earnings Conference
Operating cash burn was reduced to $3.6 million, indicating a tightening of operating expenses and movement towards achieving cash flow break-even.The following is a summary of the Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript:
以下是迪卡斯系統公司（DCTH）2024年第三季度業績發佈會的摘要：
Financial Performance:
財務表現：
Delcath Systems reported a total revenue of $11.2 million for Q3 2024, with $10 million from US revenue attributed to HEPZATO and $1.2 million from European revenue due to CHEMOSAT.
Gross margins stood impressive at 85% for the third quarter.
Operating cash burn was reduced to $3.6 million, indicating a tightening of operating expenses and movement towards achieving cash flow break-even.
迪卡斯系統報告2024年第三季度營業收入爲1120萬美元，其中來自美國HEPZATO的收入爲1000萬美元，來自歐洲CHEMOSAt的收入爲120萬美元。
第三季度毛利率表現令人印象深刻，達到了85%。
運營現金消耗減少至360萬美元，顯示出營業費用的緊縮，朝着實現現金流收支平衡的目標邁進。
Business Progress:
業務進展：
Activated 11 treatment centers for HEPZATO by the end of Q3 with an additional center activated in October, targeting a total of 15 centers by year-end and 20 by Q1 2025. The goal is to establish 30 centers by the end of 2025.
Average treatments per center post-activation were just under two treatments per month.
Plans to initiate two Phase II randomized clinical trials for liver dominant metastatic colorectal cancer and breast cancer by mid and late 2025, respectively.
到第三季度末，已激活11個HEPZATO治療中心，10月又激活了一箇中心，目標是到年底總共15箇中心，2025年第一季度達到20箇中心。目標是到2025年底建立30箇中心。
激活後的平均治療中心每月接受的治療次數接近兩次。
計劃在2025年中期和晚期分別啓動兩項針對肝主導轉移性結直腸癌和乳腺癌的第二階段隨機臨牀試驗。
Opportunities:
機會：
The commercialization and clinical progression of HEPZATO have positioned the company for rapid revenue growth and expansion into additional therapeutic indications.
Expansion plans in major European markets for CHEMOSAT, aiming to increase treating sites to support both commercial success and clinical trials.
HEPZATO的商業化和臨牀進展使公司能夠迅速實現營業收入增長，並擴展至其他治療適應症。
在主要歐洲市場擴展CHEMOSAt計劃，旨在增加治療地點以支持商業成功和臨牀試驗。
Risks:
風險：
Seasonal reductions in treatment days in Q4 due to holidays may result in temporary lower average treatment rates, affecting quarterly performance metrics temporarily.
由於假期的原因，第四季度的治療天數季節性減少，可能導致平均治療率暫時下降，影響季度業績指標。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更全面的細節，請參閱IR網站。 文章僅供投資者參考，不構成任何指導或推薦建議。
譯文內容由第三人軟體翻譯。
